Business Context and Reporting Period
This Form 8-K reports on the 2026 Annual Meeting of Stockholders held by AnaptysBio, Inc. on August 11, 2026. The filing details the outcomes of four specific proposals submitted to security holders for a vote.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results rather than financial performance data.
Material Changes and Voting Results
Four proposals were adopted at the Annual Meeting:
- Election of Directors: Hollings Renton and John P. Schmid were elected as Class III directors for three-year terms expiring in 2029.
- Auditor Ratification: KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending June 30, 2027.
- Executive Compensation: A non-binding, advisory vote approved the compensation paid to named executive officers.
- Equity Plan Amendment: Stockholders approved an amendment to the Company's 2017 Equity Incentive Plan.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document serves as a record of the completed shareholder vote.
Key Facts for Investor Verification
- Verify the specific terms of the amendment to the 2017 Equity Incentive Plan referenced in Exhibit 10.1.
- Confirm the total number of shares outstanding and voting power based on the vote tallies provided (e.g., 22,343,352 shares voted "For" auditor ratification).
- Review the Company's subsequent filings for the full financial results of the fiscal year ending June 30, 2026, as they are not included in this 8-K.